Peptide record

TPDB91755

Indolicidin indolicidin (IL) Indolicidin-Arg Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard

13 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91755

Peptide_Name

Indolicidin indolicidin (IL) Indolicidin-Arg

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP AVPpred-BWR DRAVP 2.0 CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

ILPWKWPWWPWRR-NH2

FASTA

>TPDB91755|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Cell-penetrating Peptides;Hemolysis;Toxicity|length=13
ILPWKWPWWPWRR-NH2

Formula C100H131N25O14

Absent Amino Acids ANDCEQGHMFSTYV

Common Amino Acids W

Mass 1907.30

PI 12.41

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 7

Net Charge +3

Boman Index -6.16

Hydrophobicity -1.069

Aliphatic Index 60.00

Half Life

Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour

Extinction Coefficient Cystines 27500

Absorbance 280nm 1441.83

Polar Residues 0

number

Amino Acid Distribution

A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 1 M: 0 F: 0 P: 3 S: 0 T: 0 W: 5 Y: 0 V: 0

Length

Formula

C100H131N25O14

Mass

1907.30

12.41

Net Charge

Boman Index

-6.16

Hydrophobicity

-1.069

C_terminal_Modification

Amidation

Chirality

Ionic_State

Cationic

Linear_or_Cyclic

Linear

Linearity

Linear

N_terminal_Modification

Free

Nature

Anticancer Antimicrobial

Origin

FLAK peptides Synthetic

SMILES

N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O

Evidence 1 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =64 µg/ml

Detail Source Activity Anticancer

Activity Measurement 64 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =345 µg/ml

Detail Source Activity Anticancer

Activity Measurement 345 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =200 µg/ml

Detail Source Activity Anticancer

Activity Measurement 200 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =270 µg/ml

Detail Source Activity Anticancer

Activity Measurement 270 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =290 µg/ml

Detail Source Activity Anticancer

Activity Measurement 290 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =345 µg/ml

Detail Source Activity Anticancer

Activity Measurement 345 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13.7 µM

Detail Source Activity Anticancer

Activity Measurement 13.7 µM

Target

Cancer Type Blood Cancer

Cell Line Jurkat

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2020

Evidence 8 Activity

Activity

Detail Source Activity Cell-penetrating Peptides

Target

Cell Line Hepg2 , Hek-293T And Nih/3T3 Cell Line

Source & Reference

Database Source CPPsite3.0

Source CPPsite3

Other

Source Activity Label	Source Definition
Cell-penetrating Peptides	CPPsite3.0 experimentally validated cell-penetrating peptide annotation.

CPP Category Natural residues Linear L Cationic

Source of Peptide Protein derived

Cargo Type plasmid DNA

Uptake Efficiency The highest transfection efficiencies of DNA/IL/PEI in different cells were always at N/P 5.

In Vitro or In Vivo In vitro

DSSP Secondary Structure CCCCCCSCCCTTC

DSSP_Secondary_Structure

CCCCCCSCCCTTC